Literature DB >> 30873251

Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment.

.   

Abstract

BACKGROUND: Major depression is defined as a period of depression lasting at least 2 weeks characterized by depressed mood, most of the day, nearly every day, and/or markedly diminished interest or pleasure in all, or almost all, activities. Anxiety disorders encompass a broad range of disorders in which people experience feelings of fear and excessive worry that interfere with normal day-to-day functioning.Cognitive behavioural therapy (CBT) is a form of evidence-based psychotherapy used to treat major depression and anxiety disorders. Internet-delivered CBT (iCBT) is structured, goal-oriented CBT delivered via the internet. It may be guided, in which the patient communicates with a regulated health care professional, or unguided, in which the patient is not supported by a regulated health care professional.
METHODS: We conducted a health technology assessment, which included an evaluation of clinical benefit, value for money, and patient preferences and values related to the use of iCBT for the treatment of mild to moderate major depression or anxiety disorders. We performed a systematic review of the clinical and economic literature and conducted a grey literature search. We reported Grading of Recommendations Assessment, Development, and Evaluation (GRADE) ratings if sufficient information was provided. When other quality assessment tools were used by the systematic review authors in the included studies, these were reported. We assessed the risk of bias within the included reviews. We also developed decision-analytic models to compare the costs and benefits of unguided iCBT, guided iCBT, face-to-face CBT, and usual care over 1 year using a sequential approach. We further explored the lifetime and short-term cost-effectiveness of stepped-care models, including iCBT, compared with usual care. We calculated incremental cost-effectiveness ratios (ICERs) from the perspective of the Ontario Ministry of Health and Long-Term Care and estimated the 5-year budget impact of publicly funding iCBT for mild to moderate major depression or anxiety disorders in Ontario. To contextualize the potential value of iCBT as a treatment option for major depression or anxiety disorders, we spoke with people with these conditions.
RESULTS: People who had undergone guided iCBT for mild to moderate major depression (standardized mean difference [SMD] = 0.83, 95% CI 0.59-1.07, GRADE moderate), generalized anxiety disorder (SMD = 0.84, 95% CI 0.45-1.23, GRADE low), panic disorder (small to very large effects, GRADE low), and social phobia (SMD = 0.85, 95% CI 0.66-1.05, GRADE moderate) showed a statistically significant improvement in symptoms compared with people on a waiting list. People who had undergone iCBT for panic disorder (SMD= 1.15, 95% CI: 0.94 to 1.37) and iCBT for social anxiety disorder (SMD=0.91, 95% CI: 0.74-1.07) showed a statistically significant improvement in symptoms compared with people on a waiting list. There was a statistically significant improvement in quality of life for people with generalized anxiety disorder who had undergone iCBT (SMD = 0.38, 95% CI 0.08-0.67) compared with people on a waiting list. The mean differences between people who had undergone iCBT compared with usual care at 3, 5, and 8 months were -4.3, -3.9, and -5.9, respectively. The negative mean difference at each follow-up showed an improvement in symptoms of depression for participants randomized to the iCBT group compared with usual care. People who had undergone guided iCBT showed no statistically significant improvement in symptoms of panic disorder compared with individual or group face-to-face CBT (d = 0.00, 95% CI -0.41 to 0.41, GRADE very low). Similarly, there was no statistically significant difference in symptoms of specific phobia in people who had undergone guided iCBT compared with brief therapist-led exposure (GRADE very low). There was a small statistically significant improvement in symptoms in favour of guided iCBT compared with group face-to-face CBT (d= 0.41, 95% CI 0.03-0.78, GRADE low) for social phobia. There was no statistically significant improvement in quality of life reported for people with panic disorder who had undergone iCBT compared with face-to-face CBT (SMD = -0.07, 95% CI -0.34 to 0.21).Guided iCBT was the optimal strategy in the reference case cost-utility analyses. For adults with mild to moderate major depression, guided iCBT was associated with increases in both quality-adjusted survival (0.04 quality-adjusted life-years [QALYs]) and cost ($1,257), yielding an ICER of $31,575 per QALY gained when compared with usual care. In adults with anxiety disorders, guided iCBT was also associated with increases in both quality-adjusted survival (0.03 QALYs) and cost ($1,395), yielding an ICER of $43,214 per QALY gained when compared with unguided iCBT. In this population, guided iCBT was associated with an ICER of $26,719 per QALY gained when compared with usual care. The probability of cost-effectiveness of guided iCBT for major depression and anxiety disorders, respectively, was 67% and 70% at willingness-to-pay of $100,000 per QALY gained. Guided iCBT delivered within stepped-care models appears to represent good value for money for the treatment of mild to moderate major depression and anxiety disorders.Assuming a 3% increase in access per year (from about 8,000 people in year 1 to about 32,000 people in year 5), the net budget impact of publicly funding guided iCBT for the treatment of mild to moderate major depression would range from about $10 million in year 1 to about $40 million in year 5. The corresponding net budget impact for the treatment of anxiety disorders would range from about $16 million in year 1 (about 13,000 people) to about $65 million in year 5 (about 52,000 people).People with depression or an anxiety disorder with whom we spoke reported that iCBT improves access for those who face challenges with face-to-face therapy because of costs, time, or the severity of their condition. They reported that iCBT provides better control over the pace, time, and location of therapy, as well as greater access to educational material. Some reported barriers to iCBT include the cost of therapy; the need for a computer and internet access, computer literacy, and the ability to understand complex written information. Language and disability barriers also exist. Reported limitations to iCBT include the ridigity of the program, the lack of face-to-face interactions with a therapist, technological difficulties, and the inability of an internet protocol to treat severe depression and some types of anxiety disorder.
CONCLUSIONS: Compared with waiting list, guided iCBT is effective and likely results in symptom improvement in mild to moderate major depression and social phobia. Guided iCBT may improve the symptoms of generalized anxiety disorder and panic disorder compared with waiting list. However, we are uncertain about the effectiveness of iCBT compared with individual or group face-to-face CBT. Guided iCBT represents good value for money and could be offered for the short-term treatment of adults with mild to moderate major depression or anxiety disorders. Most people with mild to moderate depression or anxiety disorders with whom we spoke felt that, despite some perceived limitations, iCBT provides greater control over the time, pace, and location of therapy. It also improves access for people who could not otherwise access therapy because of cost, time, or the nature of their health condition.

Entities:  

Mesh:

Year:  2019        PMID: 30873251      PMCID: PMC6394534     

Source DB:  PubMed          Journal:  Ont Health Technol Assess Ser        ISSN: 1915-7398


  125 in total

Review 1.  A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression.

Authors:  R Churchill; V Hunot; R Corney; M Knapp; H McGuire; A Tylee; S Wessely
Journal:  Health Technol Assess       Date:  2001       Impact factor: 4.014

2.  Estimation of utilities for the effects of depression from the SF-12.

Authors:  L A Lenert; C D Sherbourne; C Sugar; K B Wells
Journal:  Med Care       Date:  2000-07       Impact factor: 2.983

3.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

4.  The duration of major depressive episodes in the Canadian general population.

Authors:  S C Patten
Journal:  Chronic Dis Can       Date:  2001

5.  Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.

Authors:  R L Spitzer; K Kroenke; J B Williams
Journal:  JAMA       Date:  1999-11-10       Impact factor: 56.272

6.  Recurrence after recovery from major depressive disorder during 15 years of observational follow-up.

Authors:  T I Mueller; A C Leon; M B Keller; D A Solomon; J Endicott; W Coryell; M Warshaw; J D Maser
Journal:  Am J Psychiatry       Date:  1999-07       Impact factor: 18.112

7.  Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports.

Authors:  Arif Khan; Shirin Khan; Russell Kolts; Walter A Brown
Journal:  Am J Psychiatry       Date:  2003-04       Impact factor: 18.112

8.  Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care.

Authors:  M King; B Sibbald; E Ward; P Bower; M Lloyd; M Gabbay; S Byford
Journal:  Health Technol Assess       Date:  2000       Impact factor: 4.014

9.  Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial.

Authors:  Paul McCrone; Martin Knapp; Judith Proudfoot; Clash Ryden; Kate Cavanagh; David A Shapiro; Sophie Ilson; Jeffrey A Gray; David Goldberg; Anthony Mann; Isaac Marks; Brian Everitt; Andre Tylee
Journal:  Br J Psychiatry       Date:  2004-07       Impact factor: 9.319

10.  Utility scores of symptom profiles in major depression.

Authors:  Ayal Schaffer; Anthony J Levitt; Susan K Hershkop; Paul Oh; Cathy MacDonald; Krista Lanctot
Journal:  Psychiatry Res       Date:  2002-06-01       Impact factor: 3.222

View more
  18 in total

Review 1.  Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2020-11-02

2.  Internet-Delivered Cognitive Behavioural Therapy for Post-traumatic Stress Disorder or Acute Stress Disorder: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2021-06-01

3.  Health Information Technology Use among Chronic Disease Patients: An Analysis of the United States Health Information National Trends Survey.

Authors:  Geetanjali Rajamani; Elizabeth Lindemann; Michael D Evans; Raghu Pillai; Sameer Badlani; Genevieve B Melton
Journal:  Appl Clin Inform       Date:  2022-08-11       Impact factor: 2.762

4.  Improvements in Depression Outcomes Following a Digital Cognitive Behavioral Therapy Intervention in a Polychronic Population: Retrospective Study.

Authors:  Aarathi Venkatesan; Benjamin Forster; Prasanna Rao; Melissa Miller; Michael Scahill
Journal:  JMIR Form Res       Date:  2022-07-05

5.  Alcohol and drug use among clients receiving internet-delivered cognitive behavior therapy for anxiety and depression in a routine care clinic - Demographics, use patterns, and prediction of treatment completion and outcomes.

Authors:  Christopher Sundström; Michael Edmonds; Joelle N Soucy; Nickolai Titov; Blake F Dear; Heather D Hadjistavropoulos
Journal:  Internet Interv       Date:  2021-12-14

6.  Repetitive Transcranial Magnetic Stimulation for People With Treatment-Resistant Depression: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2021-05-06

7.  The Feasibility and Efficacy of a Brief Integrative Treatment for Adults With Depression and/or Anxiety: A Randomized Controlled Trial.

Authors:  Adrian L Lopresti; Stephen J Smith; Alexandra P Metse; Tiffany Foster; Peter D Drummond
Journal:  J Evid Based Integr Med       Date:  2020 Jan-Dec

8.  Implementation of e-mental health interventions for informal caregivers of adults with chronic diseases: a protocol for a mixed-methods systematic review with a qualitative comparative analysis.

Authors:  Chelsea Coumoundouros; Louise von Essen; Robbert Sanderman; Joanne Woodford
Journal:  BMJ Open       Date:  2020-06-21       Impact factor: 2.692

9.  Internet and Face-to-face Cognitive Behavioral Therapy for Postnatal Depression Compared With Treatment as Usual: Randomized Controlled Trial of MumMoodBooster.

Authors:  Jeannette Milgrom; Brian G Danaher; John R Seeley; Christopher J Holt; Charlene Holt; Jennifer Ericksen; Milagra S Tyler; Jeff M Gau; Alan W Gemmill
Journal:  J Med Internet Res       Date:  2021-12-08       Impact factor: 5.428

Review 10.  Meta-analytic review of online guided self-help interventions for depressive symptoms among college students.

Authors:  Liang Ma; Cong Huang; Rimeng Tao; Zeshi Cui; Philip Schluter
Journal:  Internet Interv       Date:  2021-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.